Study identification

EU PAS number

EUPAS1000000156

Study ID

1000000156

Official title and acronym

Open Triple Therapy for Chronic Obstructive Pulmonary Disease: Patterns of Prescription, Exacerbations and Healthcare Costs From a Large Italian Claims Database

DARWIN EU® study

No

Study countries

Italy

Study description

An observational retrospective non-interventional cohort study of administrative halthcare data aimed to identify subjects with chronic obstructive pulmonary disease (COPD) treated with extemporaneous combination of inhaled corticosteroids (ICS)/long-actingβ2-agonist (LABA) and long-acting muscarinic antagonist (LAMA), namely open TT, and to describe the pharmacological strategy, the spirometry use, the exacerbations occurrence and the costs reimbursed by the Italian National Health System (SSN) in 1-year follow-up.

Study status

Finalised
Research institutions and networks

Institutions

Contact details

Letizia Dondi 0009-0001-3168-6856

Primary lead investigator
ORCID number:
0009-0001-3168-6856

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Date of final study report

Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

This research received the unconditional support of Glaxo Smith Kline, which did not have a role in the study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the article for publication. The grant number is not available.
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable